Aquestive Therapeutics (AQST) Shares Outstanding (Weighted Average) (2017 - 2025)
Aquestive Therapeutics has reported Shares Outstanding (Weighted Average) over the past 9 years, most recently at $106.9 million for Q4 2025.
- Quarterly results put Shares Outstanding (Weighted Average) at $106.9 million for Q4 2025, up 23.29% from a year ago — trailing twelve months through Dec 2025 was $106.9 million (up 23.29% YoY), and the annual figure for FY2025 was $106.9 million, up 23.29%.
- Shares Outstanding (Weighted Average) for Q4 2025 was $106.9 million at Aquestive Therapeutics, down from $110.6 million in the prior quarter.
- Over the last five years, Shares Outstanding (Weighted Average) for AQST hit a ceiling of $110.6 million in Q3 2025 and a floor of $35.6 million in Q1 2021.
- Median Shares Outstanding (Weighted Average) over the past 5 years was $59.3 million (2023), compared with a mean of $66.1 million.
- Biggest five-year swings in Shares Outstanding (Weighted Average): rose 5.94% in 2021 and later surged 58.52% in 2024.
- Aquestive Therapeutics' Shares Outstanding (Weighted Average) stood at $38.1 million in 2021, then rose by 27.99% to $48.7 million in 2022, then rose by 25.69% to $61.3 million in 2023, then skyrocketed by 41.58% to $86.7 million in 2024, then grew by 23.29% to $106.9 million in 2025.
- The last three reported values for Shares Outstanding (Weighted Average) were $106.9 million (Q4 2025), $110.6 million (Q3 2025), and $99.3 million (Q2 2025) per Business Quant data.